Table 1 Described oncogenic alterations in chromatin regulatory factors that are candidate drivers in at least one tissue

ARID1A

Mutated in cc ovarian carcinoma and RCC (CGC), bladder [25], HCC [26], endometrium [27], colorectal [28], gastric adenocarcinoma [29], pancreatic cancer [30], lung adenocarcinoma [31], Burkitt lymphoma [32] and aggressive neuroblastoma [33].

Down-regulated in aggressive breast cancer [34],

KMT2C

Mutated in medulloblastoma (CGC), HCC [26], bladder [25], prostate cancer [35], colorectal cancer [36], gastric adenocarcinoma [29], NSCLC [37], breast cancer [38] and pancreatic cancer [30].

Deleted in leukemia [39].

DNMT3A

Mutated in AML (CGC), ALL and lung cancer [40].

Over-expressed in ovarian aggressive tumors [41].

KDM6A

Mutated in kidney, esophageal squamous cell carcinoma, multiple myeloma (CGC), lung cancer [42], medulloblastoma [43], ccRCC [44], bladder [25] and prostate [35].

Over-expressed in breast tumors with poor prognosis [45].

Deleted in lung cancer [46].

PBRM1

Mutated in ccRCC, breast (CGC) and pancreatic cancer [47].

NSD1

Mutated in AML (CGC) and NMSC [10].

Gained in lung adenocarcinoma of never-smokers [48].

TET2

Mutated in MDS (CGC), CMML and AML [49].

SETD2

Mutated in ccRCC (CGC).

Down-regulated in breast tumors [50].

SMARCA4

Mutated in NSCLC (CGC), lung adenocarcinoma [31], medulloblastoma [43] and Burkitt lymphoma [32].

Over-expressed in glioma [51] and in melanoma progression [52].

Gained in lung [42].

KMT2D

Mutated in medulloblastoma, bladder [25], renal cancer (CGC), DLBCL [53].

Over-expressed in breast and colon tumors [54].

CHD4

Mutated in high MSI gastric and colorectal cancers [55].

Down-regulated in gastric and colorectal cancers [55].

NCOR1

Mutated in breast [56] and bladder cancer [25].

Down-regulated in aggressive breast tumors [57].

EP300

Mutated in colorectal, breast and pancreatic cancers, ALL, AML, DLBCL (CGC), bladder [25], SCLC [58] and endometrium [27].

Up-regulated in esophageal squamous cell carcinoma [59] and advanced HCC [60].

Loss of heterozygosity in glioblastoma [61].

KDM5C

Mutated in ccRCC (CGC).

ARID2

Mutated in hepatocellular carcinoma (CGC), melanoma [62], NSCLC [63] and pancreatic cancer [30].

Deleted in NSCLC [63].

ATF7IP

-

ASXL1

Mutated in MDS and CMML (CGC), myeloproliferative neoplasm; [64], AML with myelodysplasia-related changes [65] and castration-resistant prostate cancer [66].

MLL

Mutated in AML, ALL (CGC), bladder [25], SCLC [58], HCC [26] and gastric tumors [29].

BAZ2A

Over-expressed in CLL [67].

CHD3

Mutated in high MSI gastric and colorectal cancers [55].

ATRX

Mutated in pediatric glioblastoma, neuroendocrine pancreatic tumors (CGC) and high grade adult gliomas [68].

ARID1B

Mutated in breast tumors [56].

MBD1

Over-expressed in pancreatic cancer [69].

BAP1

Mutated in uveal melanoma, breast, NSCLC and RCC (CGC).

Over-expressed in NSCLC with good prognosis [70].

INO80

-

CHD2

Mutated in high MSI gastric and colorectal cancers [55] and CLL [71].

Down-regulated in relapsed colon cancer [72].

ARID4A

-

DOT1L

-

ASH1L

Mutated in lung cancer cell lines [42].

Gained in hepatocellular carcinoma [73].

BPTF

Gained in neuroblastoma and lung cancer [74].

RTF1

-

PHC3

Mutated and lost in osteosarcoma [75].

SMARCA2

Mutated in NMSC [76] and CLL [77].

Down-regulated in lung adenocarcinoma [78] and gastric cancer [79].

Amplified in AML [80].

SETDB1

Recurrently amplified and over-expressed in melanoma [81].